IP Library Granted Patent US 10,150,884
Granted Patent B2
US 10,150,884 · App. 14/826,865 · Granted Dec 11, 2018

Composition, methods and devices useful for manufacturing of implantable articles

Inventors: Kayla Wroblesky (Freehold, NJ); Peter D. Gabriele (Perkasie, PA); Jeremy J. Harris (Doylestown, PA); Carissa Smoot (Sellersville, PA); Charles Brendan Nicholson (Quakertown, PA); Austin Robertson (Sellersville, PA); Julia Donnelly (Chalfont, PA)
Assignee: THE SECANT GROUP, LLC
C09D167/00A61L27/18A61L27/222A61L27/24A61L27/56C09D189/00B33Y10/00B33Y70/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,150,884
App. No.
14/826,865
Granted
Dec 11, 2018
Kind
B2
Abstract

The application is directed to aqueous dispersible biodegradable compositions of esters which are the condensation reaction product of a polyol and a diacid which are within a matrix of hydrated polypeptide. The compositions are useful in additive manufacturing and other applications for use with implantable articles. In some embodiments, the ester in the compositions is the product of a glyercol-sebacic acid condensation reaction.

Claims (28)

1. A composition comprising:

water;

an ester of a polyol and a diacid; and

a polypeptide;

wherein the composition comprises a uniform aqueous dispersion of the ester and the polypeptide in the water.

2. The composition according to claim 1 , wherein the ester comprises a glyercol-sebacic acid ester compound.

3. The composition according to claim 2 , wherein the glyercol-sebacic acid ester compound is a polymeric compound having a molecular weight greater than 10,000.

4. The composition according to claim 3 , further comprising a glyercol-sebacic acid ester compound having a molecular weight less than 10,000.

5. The composition according to claim 2 , wherein the composition comprises:

about 30% to about 85% by weight water;

about 10% to about 60% of the glyercol-sebacic acid ester compound; and

about 0.1% to about 30% polypeptide.

6. The composition according to claim 2 , wherein the composition comprises:

about 40% to about 85% by weight water;

about 10% to about 50% of the glyercol-sebacic acid ester compound; and

about 5% to about 30% polypeptide.

7. The composition according to claim 1 , wherein the ester is functionalized.

8. The composition according to claim 1 , further comprising a bioactive material.

9. The composition of claim 8 , wherein the bioactive material is selected from the group consisting of vitamins, minerals, tocopherol, ascorbate, retinoic acid, and combinations thereof.

10. The composition of claim 8 , wherein the bioactive material comprises cells.

11. The composition of claim 8 , wherein the bioactive material is selected from the group consisting of peptide sequences, growth factors, proteoglycans, glycoproteins, glycosaminoglycans, polysaccharides, nutrients, cytokines, hormones, angiogenic factors, immunomodulatory factors, drugs, and combinations thereof.

12. The composition according to claim 1 , further comprising a fatty acid.

13. The composition according to claim 12 , wherein the fatty acid is co-esterified with the polyol-diacid ester.

14. The composition according to claim 1 , wherein the polypeptide is collagen.

15. The composition according to claim 1 , wherein the polypeptide is gelatin.

16. The composition according to claim 1 , wherein the composition consists of 8-12% by weight gelatin, 35-40% by weight glyercol-sebacic acid ester compound, and the balance water.

17. The composition according to claim 1 , wherein the diacid is sebacic acid.

18. The composition of claim 1 , wherein the ester is aqueously dispersible and biodegradable and the polypeptide is a hydrated matrix in the composition.

Assignments (3)
SECURITY INTEREST Recorded May 28, 2021
From: THE SECANT GROUP, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 056421/0952 →
CHANGE OF NAME Recorded Nov 2, 2018
From: SECANT MEDICAL, INC.
To: THE SECANT GROUP, LLC
Reel/Frame 047404/0763 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2015
From: WROBLESKY, KAYLA; GABRIELE, PETER D.; HARRIS, JEREMY J.; SMOOT, CARISSA; NICHOLSON, CHARLES BRENDAN; ROBERTSON, AUSTIN; DONNELLY, JULIA
To: SECANT MEDICAL, INC.
Reel/Frame 036778/0649 →
Continuity (3)
Provisional Application 62037640 · Aug 15, 2014
Provisional Application 62037425 · Aug 14, 2014
Related Publication 20160046832A1 · Feb 18, 2016
Cited By (1)
US 12,514,956